ZYX and breast carcinoma: One of the rare mechanistic studies revealed that, in breast cancer cells, cytoplasmic zyxin can inhibit the HIPPO pathway, thereby promoting cell proliferation via nuclear translocation of the proliferation-associated co-transcriptional activator yes-associated protein (YAP) [136].